The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the cell therapy BCB-276 as a potential treatment for diffuse intrinsic…
Glioma
The LY6H and GRM3 proteins could serve as potential biomarkers of glioma-related epilepsy (GRE), according to a study. Among people with gliomas, both proteins…
Personalized dosing and monitoring of drug levels may be necessary for children with low-grade glioma treated with Mekinist (trametinib), according to a study. The…
CAN-2409 (aglatimagene besadenovec), Candel Therapeutics‘ investigational immunotherapy, was safe and demonstrated potential survival benefits in patients with high-grade glioma, an aggressive type of…
Combining VXM01, an experimental anticancer vaccine, with Bavencio (avelumab), which activates the immune system to attack cancer cells, was well tolerated in a…
Avapritinib, an approved orally available medication, reduced tumor size in a subset of children and young adults with treatment-resistant high-grade gliomas, a study shows.
Adding the investigational therapy LAM561 to standard of care treatment may delay disease progression or death in people with newly diagnosed glioblastoma whose tumors exhibit…
Tumors in children with aggressive gliomas that formed in the spinal cord all exhibited genetic changes that might be able to be targeted therapeutically,…
Calidi Biotherapeutics has begun recruiting adults with high-grade glioma for a Phase 1b/2 clinical trial to study the effects of multiple doses of…
The U.S. Food and Drug Administration (FDA) has agreed to a priority review of a Chimerix application seeking accelerated approval of dordaviprone, its oral…
